Biomea Fusion Stock (NASDAQ:BMEA)
Previous Close
$7.50
52W Range
$3.61 - $22.74
50D Avg
$6.04
200D Avg
$11.54
Market Cap
$284.25M
Avg Vol (3M)
$918.50K
Beta
-0.49
Div Yield
-
BMEA Company Profile
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.